Dbv Technologies S A 's Comment on Competition and Industry Peers
The competitive landscape for allergy therapeutics includes pharmaceutical and biotechnology companies, universities, and research entities developing treatments for food allergies. Competitors possess greater resources and experience, conducting studies on allergen desensitization methods such as oral immunotherapy (OIT), sublingual immunotherapy (SLIT), subcutaneous immunotherapy (SCIT), omalizumab immunotherapy (OMIT), INT immunotherapy, synthetic allergens, small molecule inhibitors, and combination therapies. Monoclonal antibodies, alone or combined with allergen immunotherapy, also represent significant competition.
Palforzia, a peanut flour formulation developed by Aimmune Therapeutics, Inc., is the only treatment approved by the U.S. Food and Drug Administration (FDA) and the European Commission for peanut allergy in children aged 1 to 17. Nestlé S.A. acquired Aimmune in October 2020 and subsequently divested Palforzia to Stallergenes Greer in September 2023. Stallergenes Greer intends to discontinue Palforzia commercialization by July 31, 2026. Additionally, Xolair (omalizumab) is FDA-approved for reducing allergic reactions and the risk of anaphylaxis, serving as another competitor in the allergy treatment market.
Immunovant Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases by leveraging their expertise in research and development, clinical trials, and regulatory approvals. Their business model revolves around discovering innovative treatments, conducting rigorous testing, and seeking regulatory clearance to bring their products to market and improve patient outcomes.
Halozyme Therapeutics Inc is a biotechnology company that primarily focuses on developing and commercializing novel oncology therapies. Their business model involves leveraging their proprietary enzyme technology to improve the delivery and effectiveness of therapeutic drugs. By partnering with pharmaceutical companies, Halozyme aims to license their technology and collaborate on the development and commercialization of innovative therapies for various diseases.
Ladrx Corporation operates as a global technology solutions provider, offering a range of products and services in various industries. Their business model revolves around leveraging innovative technologies to develop tailored solutions for their clients, with a focus on enhancing operational efficiency and driving digital transformation. By combining their expertise in multiple domains and maintaining strong partnerships, Ladrx aims to deliver value-driven solutions to meet the evolving needs of businesses worldwide.
Sources:
Dbv Technologies S a’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dbv Technologies S a versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
